Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation

By Michael Erman, Patrick Wingrove and Ahmed Aboulenein NEW YORK/WASHINGTON (Reuters) – The blood thinner Eliquis from Bristol Myers Squibb, Pfizer’s breast cancer drug Ibrance and AbbVie’s leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S. price negotiations for 2026, according to five Wall Street and academic analyses shared with Reuters. Last year Congress passed the Inflation Reduction Act (IRA), giving the U.S. government power to start the first price negotiations over prescription drugs for its Medicare health program covering more than 60 milli…

Read More